JP Morgan Chase
VIVO

JP Morgan Chase’s Meridian Bioscience Inc VIVO Stock Holding History

JP Morgan Chase’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-381,880
Closed -$12.7M – 7519
2022
Q4 		$12.7M Buy
381,880
+180,797
+90% +$5.82M ﹤0.01% 2046
2022
Q3 		$6.34M Buy
201,083
+101,051
+101% +$3.27M ﹤0.01% 2519
2022
Q2 		$3.04M Sell
100,032
-56,599
-36% -$1.53M ﹤0.01% 3210
2022
Q1 		$4.07M Buy
156,631
+21,777
+16% +$518K ﹤0.01% 3180
2021
Q4 		$2.75M Sell
134,854
-34,045
-20% -$653K ﹤0.01% 3589
2021
Q3 		$3.25M Buy
168,899
+106,030
+169% +$2.11M ﹤0.01% 3386
2021
Q2 		$1.39M Buy
62,869
+1,231
+2% +$26.1K ﹤0.01% 4059
2021
Q1 		$1.62M Sell
61,638
-71,753
-54% -$1.71M ﹤0.01% 3870
2020
Q4 		$2.49M Buy
133,391
+75,450
+130% +$1.41M ﹤0.01% 3328
2020
Q3 		$999K Buy
57,941
+2,757
+5% +$53.6K ﹤0.01% 3646
2020
Q2 		$1.28M Sell
55,184
-624,334
-92% -$9.05M ﹤0.01% 3371
2020
Q1 		$5.71M Buy
679,518
+420,681
+163% +$3.54M ﹤0.01% 2154
2019
Q4 		$2.53M Sell
258,837
-430,850
-62% -$4.04M ﹤0.01% 3208
2019
Q3 		$6.54M Buy
689,687
+464,939
+207% +$4.9M ﹤0.01% 2470
2019
Q2 		$2.63M Sell
224,748
-41,446
-16% -$499K ﹤0.01% 3190
2019
Q1 		$4.69M Sell
266,194
-33,778
-11% -$562K ﹤0.01% 2638
2018
Q4 		$5.21M Sell
299,972
-285,570
-49% -$4.87M ﹤0.01% 2543
2018
Q3 		$8.72M Sell
585,542
-38,953
-6% -$604K ﹤0.01% 2309
2018
Q2 		$9.93M Buy
624,495
+30,589
+5% +$456K ﹤0.01% 2150
2018
Q1 		$8.43M Sell
593,906
-29,425
-5% -$435K ﹤0.01% 2146
2017
Q4 		$8.73M Buy
623,331
+621,349
+31,350% +$9.1M ﹤0.01% 2231
2017
Q3 		$28K Buy
1,982
+280
+16% +$4K ﹤0.01% 4578
2017
Q2 		$27K Sell
1,702
-224,345
-99% -$3.23M ﹤0.01% 4483
2017
Q1 		$3.12M Buy
226,047
+10,939
+5% +$153K ﹤0.01% 2758
2016
Q4 		$3.81M Buy
215,108
+128,184
+147% +$2.25M ﹤0.01% 2663
2016
Q3 		$1.68M Sell
86,924
-53,823
-38% -$1.05M ﹤0.01% 2900
2016
Q2 		$2.75M Sell
140,747
-96,328
-41% -$1.89M ﹤0.01% 2634
2016
Q1 		$4.89M Sell
237,075
-2,737
-1% -$53.9K ﹤0.01% 2236
2015
Q4 		$4.92M Buy
239,812
+3,987
+2% +$76.4K ﹤0.01% 2236
2015
Q3 		$4.03M Buy
+235,825
New +$4.31M ﹤0.01% 2356
2014
Q1 		– Sell
-47,563
Closed -$1.26M – 4011
2013
Q4 		$1.26M Sell
47,563
-9,927
-17% -$244K ﹤0.01% 3033
2013
Q3 		$1.36M Sell
57,490
-12,773
-18% -$298K ﹤0.01% 3066
2013
Q2 		$1.51M Buy
+70,263
New +$1.52M ﹤0.01% 2995

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

JP Morgan Chase's VIVO Position: Q1 2023 in Review

JP Morgan Chase sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 381,880 shares — an estimated $12.7M sold.

JP Morgan Chase first reported a position in VIVO in Q2 2013 and held it in 33 quarters. The position peaked at $12.7M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • JP Morgan Chase reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • JP Morgan Chase sold 381,880 Meridian Bioscience Inc shares in Q1 2023, an estimated $12.7M.
  • JP Morgan Chase first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 33 quarters.
  • JP Morgan Chase's Meridian Bioscience Inc position peaked at $12.7M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.